TRDA vs. WVE, IMCR, ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, and OCUL
Should you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Wave Life Sciences (WVE), Immunocore (IMCR), ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.
Entrada Therapeutics vs.
Wave Life Sciences (NASDAQ:WVE) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.
89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are owned by institutional investors. 29.1% of Wave Life Sciences shares are owned by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Entrada Therapeutics has higher revenue and earnings than Wave Life Sciences. Wave Life Sciences is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
Wave Life Sciences received 346 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Entrada Therapeutics an outperform vote while only 67.78% of users gave Wave Life Sciences an outperform vote.
In the previous week, Wave Life Sciences had 17 more articles in the media than Entrada Therapeutics. MarketBeat recorded 22 mentions for Wave Life Sciences and 5 mentions for Entrada Therapeutics. Wave Life Sciences' average media sentiment score of 0.76 beat Entrada Therapeutics' score of 0.76 indicating that Wave Life Sciences is being referred to more favorably in the media.
Entrada Therapeutics has a net margin of 25.53% compared to Wave Life Sciences' net margin of -66.50%. Entrada Therapeutics' return on equity of 16.11% beat Wave Life Sciences' return on equity.
Wave Life Sciences presently has a consensus price target of $22.60, indicating a potential upside of 162.18%. Entrada Therapeutics has a consensus price target of $25.67, indicating a potential upside of 168.48%. Given Entrada Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Entrada Therapeutics is more favorable than Wave Life Sciences.
Wave Life Sciences has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.14, suggesting that its stock price is 114% less volatile than the S&P 500.
Summary
Entrada Therapeutics beats Wave Life Sciences on 11 of the 18 factors compared between the two stocks.
Get Entrada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entrada Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TRDA) was last updated on 3/29/2025 by MarketBeat.com Staff
Buy TRDA Stock Free TRDA Stock Alerts